SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
The US FDA approves our CRISPR/Cas9 gene-edited treatment in sickle cell disease
Vertex receives European Commission approval for its fourth medicine, for eligible children with cystic fibrosis aged 2 to 5 years old
Our CRISPR/Cas9 gene-edited treatment for sickle cell disease and transfusion-dependent beta thalassemia is approved by the UK MHRA
Vertex announces Q3 2023 financial results
Vertex to share new data on investigational therapy for the treatment of sickle cell disease and beta thalassemia at the 2023 American Society of Hematology (ASH) Annual Meeting
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Find a Vertex clinical trial
Volunteers who participate in clinical trials
help make new medicines a reality.
Featured Stories
Listen to Jason McCartney, Senior Director, Medicinal Chemistry, discuss an overview of the drug discovery process at Vertex Pharmaceuticals.
Join us as we celebrate 15 years of giving back at Vertex.
Individuals living with severe sickle cell disease report higher exposure to health care prejudice, according to new research by our Health Economics and Outcomes Research (HEOR) team.
Listen to Jason McCartney, Senior Director, Medicinal Chemistry, discuss an overview of the drug discovery process at Vertex Pharmaceuticals.
Join us as we celebrate 15 years of giving back at Vertex.
Individuals living with severe sickle cell disease report higher exposure to health care prejudice, according to new research by our Health Economics and Outcomes Research (HEOR) team.
